BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 638014)

  • 1. Studies with a spontaneous mouse tumor. I. Growth in normal mice and response to Corynebacterium parvum.
    Woodruff MF; Whitehead VL; Speedy G
    Br J Cancer; 1978 Mar; 37(3):345-55. PubMed ID: 638014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma.
    Purnell DM; Bartlett GL; Kreider JW; Biro TG
    Cancer Res; 1977 Apr; 37(4):1137-40. PubMed ID: 844041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of preoperative C. parvum vaccine to modify secondary disease following excision of two non-immunogenic murine carcinomas.
    Hewitt HB; Blake ER
    Br J Cancer; 1978 Aug; 38(2):219-23. PubMed ID: 698036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Fc receptor expression by a sub-population of murine intra-tumour macrophages following intravenous Corynebacterium parvum therapy.
    Moore K; McBride WH
    Br J Cancer; 1983 Jun; 47(6):797-802. PubMed ID: 6860547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of local injection of Corynebacterium parvum on the growth of a murine fibrosarcoma.
    Woodruff MF; Dunbar N
    Br J Cancer; 1975 Jul; 32(1):34-41. PubMed ID: 1080671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Corynebacterium parvum on tumor growth in normal and athymic (nude) mice.
    Woodruff MF; Warner NL
    J Natl Cancer Inst; 1977 Jan; 58(1):111-6. PubMed ID: 299893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effect of prolonged Corynebacterium parvum and cyclophosphamide administration on the growth of established tumors.
    Fisher B; Wolmark N; Saffer E; Fisher ER
    Cancer; 1975 Jan; 35(1):134-43. PubMed ID: 1109767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of cancer using Corynebacterium parvum: similarity of two preparations in four animal tumor models.
    Bartlett GL; Kreider JW; Purnell DM
    Cancer; 1980 Aug; 46(4):685-91. PubMed ID: 7397633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fc receptor-bearing and phagocytic cells in syngeneic tumours of C. parvum- and carrageenan-treated mice.
    Thomson AW; Cruickshank N; Fowler EF
    Br J Cancer; 1979 May; 39(5):598-602. PubMed ID: 486317
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of C. parvum and active specific immunotherapy on intracerebral transplants of a murine fibrosarcoma.
    Woodruff MF; Hitchcock E; Whitehead VL
    Br J Cancer; 1977 May; 35(5):687-92. PubMed ID: 861152
    [No Abstract]   [Full Text] [Related]  

  • 11. Antitumor activity of killed Corynebacterium parvum suspensions in a murine mammary adenocarcinoma CaD2) system.
    Purnell DM; Otterstrom JR; Bartlett GL; Kreider JW
    J Natl Cancer Inst; 1976 Jun; 56(6):1171-5. PubMed ID: 994219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C. parvum treatment of transplanted rat tumours of spontaneous origin.
    Willmott N; Pimm MV; Baldwin RW
    Int J Cancer; 1979 Sep; 24(3):323-8. PubMed ID: 385514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Corynebacterium parvum on the response to irradiation of a C3H fibrosarcoma.
    Suit HD; Sedlacek R; Wagner M; Orsi L; Silobrcic V; Rothman KJ
    Cancer Res; 1976 Apr; 36(4):1305-14. PubMed ID: 1260756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rejection of mammary adenocarcinoma cell tumors in DBA/2 mice immunocompromised by thymectomy and treatment with antithymocyte serum.
    Likhite VV
    J Immunol; 1975 Jun; 114(6):1736-42. PubMed ID: 1092759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of concomitant immunity after radiation therapy and immunotherapy in a syngeneic murine tumour system.
    Deneufbourg JM
    Acta Radiol Oncol; 1982; 21(5):345-8. PubMed ID: 6297254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moderate to high dose cyclophosphamide and intercalated Corynebacterium parvum in patients with metastatic lung cancer.
    Thatcher N; Honeybourne D; Wagstaff J; Carroll KB; Barber PV; Morrison JB; Crowther D
    Br J Dis Chest; 1984 Jan; 78(1):89-97. PubMed ID: 6318791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiolabelling of Corynebacterium parvum and its distribution in mice.
    Sadler TE; Cramp WA; Castro JE
    Br J Cancer; 1977 Mar; 35(3):357-68. PubMed ID: 851511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of Corynebacterium parvum and surgery on the Lewis lung carcinoma and its metastases.
    Sadler TE; Castro JE
    Br J Surg; 1976 Apr; 63(4):292-6. PubMed ID: 1276661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responsiveness of senescent mice to the antitumor properties of Corynebacterium parvum.
    Yuhas JM; Ullrich RL
    Cancer Res; 1976 Jan; 36(1):161-6. PubMed ID: 1247995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of the incidence of death with spontaneous tumours in DBA/2 mice after Corynebacterium parvum-mediated rejection of syngeneic tumours.
    Likhite VV
    Nature; 1976 Feb; 259(5542):397-9. PubMed ID: 1250378
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.